IGF-1 DES, formally IGF-1 des(1-3), is a truncated version of insulin-like growth factor 1 with its first three N-terminal amino acids removed, a small edit that sharply weakens its grip on the binding proteins that normally hold circulating IGF-1 in reserve. In laboratory models that change makes it substantially more potent than intact IGF-1 on a molar basis while giving it a much shorter half-life, the profile behind most of the research and community interest in the molecule. It is not an approved drug, and the honest starting point is that its reputation rests largely on cell and animal pharmacology rather than controlled human evidence.
IGF-1 DES is a 67-amino-acid analog of insulin-like growth factor 1, missing the N-terminal residues glycine, proline, and glutamate, and it carries no approved human therapeutic indication.
The des(1-3) label is a literal description: des means deleted, and (1-3) names the three positions taken off the front of the chain. Native IGF-1 is a single-chain, 70-residue polypeptide of about 7.6 kilodaltons held in a compact fold by three disulfide bonds; the des variant is that same molecule minus glycine, proline, and glutamate at positions one through three. The reported effect is out of proportion to the edit, because the deleted glutamate is one of the contacts that let the binding proteins hold onto the molecule.
| Property | Native IGF-1 | IGF-1 DES |
|---|---|---|
| Chain length | 70 amino acids | 67 amino acids |
| Molecular mass | ~7.6 kDa | Slightly lower |
| IGFBP affinity | Full | ~10x weaker in reported assays |
| Free fraction at tissue | Largely sequestered | Largely free |
Removing the first three N-terminal residues leaves a 67-amino-acid chain and weakens IGF binding protein affinity by roughly an order of magnitude, so far more of the peptide stays free to reach the type 1 IGF receptor.
IGF-1 DES engages the same receptor as intact IGF-1, the type 1 IGF receptor, a transmembrane receptor tyrosine kinase that autophosphorylates and recruits adaptor proteins once the peptide binds. What sets the des variant apart is not a different receptor but a different availability profile: because it binds the IGF binding proteins weakly, less of it is captured and held in reserve, so a greater share is immediately free to occupy receptors near where it is introduced. That availability, paired with a short circulating half-life, is why the literature describes its effect as strong but local and transient rather than sustained and systemic.
IGF-1 DES signals through the type 1 IGF receptor and its downstream PI3K/Akt and Ras/MAPK pathways, and its distinguishing feature is pharmacokinetic, with weak binding-protein affinity leaving more free peptide to act locally.
The uses attributed to IGF-1 DES split cleanly into what a laboratory has validated and what a community has claimed, and blurring the two is the central error in most coverage. In controlled settings it is a research reagent for probing IGF-1 receptor signaling and tissue growth; in peptide and bodybuilding circles it is discussed as a way to encourage growth in a specific muscle by introducing it nearby, on the theory that its short half-life keeps the effect regional.
IGF-1 DES is an established research reagent for studying IGF-1 receptor signaling, but its localized-hypertrophy reputation rests on preclinical pharmacology rather than controlled human trials, and it has no approved clinical indication.
No validated human dosing regimen for IGF-1 DES exists, and that absence has to anchor any honest discussion rather than any specific microgram figure. In research the material is handled as a lyophilized powder reconstituted to a defined concentration for an assay or animal protocol, with amounts expressed in micrograms and set by the experimental design, not a therapeutic target. The molecule's very short half-life is the dominant practical fact behind why protocols place it close in time and place to where its transient effect is wanted.
No validated human dose for IGF-1 DES exists in the literature, and any microgram figure circulating on forums is anecdote carrying the added risks of unverified purity, reconstitution error, and no medical monitoring.
The safety picture is dominated by the fact that potent, receptor-level growth signaling carries the same category of risk that makes IGF pathway manipulation a serious matter, and the molecule has never been characterized for human safety. The most consequential concern is not an acute side effect but the long-horizon biology: IGF-1 signaling drives cell proliferation and survival, the exact behavior tumors exploit.
IGF-1 DES has never been characterized for human safety, and its receptor-level growth signaling carries theoretical hypoglycemia and cancer-promotion risks that make prior or active cancer, pregnancy, and endocrine disorders particular reasons for avoidance.
IGF-1 DES is not approved by the US Food and Drug Administration, or by comparable regulators, as a drug for any human therapeutic use, and it is not a dietary supplement ingredient either. It is sold instead as a research chemical labeled for laboratory use only and not for human consumption, a designation signaling that the product has not been evaluated for use in people and that the seller sits outside the medical supply chain.
IGF-1 DES occupies a research-only regulatory zone, unapproved by the FDA for any human use, sold as a not-for-human-consumption research chemical, and prohibited for competitive athletes under the World Anti-Doping Agency code.
IGF-1 DES is most often set against IGF-1 LR3, and the two make a clean study in opposite kinetic personalities. Both are engineered to escape the IGF binding proteins, but DES does it by deleting the N-terminal tripeptide while LR3 adds a 13-amino-acid extension and swaps an arginine for a glutamate at position three. The result is a short, intense, local effect for DES against a stable, systemic, hours-long profile for LR3.
| Property | IGF-1 DES | IGF-1 LR3 |
|---|---|---|
| IGFBP escape | N-terminal tripeptide deletion | N-terminal extension plus position-3 substitution |
| Half-life | Very short | Many hours |
| Effect profile | Intense, local, transient | Sustained, systemic |
| Relative potency | High acute local potency | Somewhat less acute, longer acting |
IGF-1 DES and IGF-1 LR3 both evade the IGF binding proteins but differ in kinetics, DES acting as a short, local, potent pulse and LR3 as a sustained systemic exposure, while both share the same unapproved status and growth-signaling safety concerns.
The evidentiary base is much thinner than the molecule's popularity suggests. What is genuinely established comes from cell culture and animal work: the truncated peptide binds the IGF-1 receptor, evades the binding proteins, is more potent than intact IGF-1 in those systems, and stimulates the expected growth responses. What does not exist is a body of controlled human trials showing it safely and meaningfully builds muscle, improves performance, or heals tissue in people.
The established evidence for IGF-1 DES is preclinical, covering receptor binding and higher in vitro potency than intact IGF-1, while controlled human trials demonstrating muscle, performance, or healing benefit are essentially absent.
As a peptide, IGF-1 DES is chemically fragile, and its handling follows the same principles as other lyophilized research peptides. The freeze-dried powder is comparatively stable, while the reconstituted solution is far more vulnerable to hydrolysis, oxidation, and microbial contamination, which is why storage tightens considerably once the material is in solution.
IGF-1 DES is stored cold as a lyophilized powder and refrigerated with a short use window once reconstituted, because heat, light, and repeated freeze-thaw cycles degrade the peptide and silently reduce its activity.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 DES. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
